Short Interest in Aziyo Biologics, Inc. (NASDAQ:AZYO) Decreases By 27.6%

Aziyo Biologics, Inc. (NASDAQ:AZYOGet Rating) was the recipient of a significant decrease in short interest in July. As of July 15th, there was short interest totalling 4,200 shares, a decrease of 27.6% from the June 30th total of 5,800 shares. Based on an average daily trading volume, of 6,300 shares, the short-interest ratio is currently 0.7 days. Approximately 0.1% of the company’s stock are sold short.

Aziyo Biologics Stock Performance

Shares of NASDAQ AZYO opened at $6.55 on Tuesday. The firm’s 50 day moving average price is $6.37 and its 200-day moving average price is $6.18. Aziyo Biologics has a 52-week low of $4.10 and a 52-week high of $9.76. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.34.

Aziyo Biologics (NASDAQ:AZYOGet Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.02. Aziyo Biologics had a negative net margin of 60.68% and a negative return on equity of 260.23%. The firm had revenue of $11.50 million during the quarter, compared to analysts’ expectations of $10.77 million. During the same period in the previous year, the company earned ($0.50) earnings per share. On average, research analysts forecast that Aziyo Biologics will post -2.13 earnings per share for the current year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Aziyo Biologics in a research note on Tuesday, May 24th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aziyo Biologics stock. Endurant Capital Management LP increased its stake in shares of Aziyo Biologics, Inc. (NASDAQ:AZYOGet Rating) by 3.1% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,109,479 shares of the company’s stock after purchasing an additional 33,839 shares during the period. Aziyo Biologics makes up 1.7% of Endurant Capital Management LP’s investment portfolio, making the stock its 16th largest holding. Endurant Capital Management LP owned 8.18% of Aziyo Biologics worth $6,601,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 88.61% of the company’s stock.

Aziyo Biologics Company Profile

(Get Rating)

Aziyo Biologics, Inc, a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device.

Featured Articles

Want More Great Investing Ideas?

Receive News & Ratings for Aziyo Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aziyo Biologics and related companies with MarketBeat.com's FREE daily email newsletter.